{"name":"MCNEIL CONS","slug":"mcneil-cons","ticker":"","exchange":"","domain":"mcneilcons.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Methylphenidate extended-release; Atomoxetine","genericName":"Methylphenidate extended-release; Atomoxetine","slug":"methylphenidate-extended-release-atomoxetine","indication":"Attention-deficit/hyperactivity disorder (ADHD) in children and adults","status":"marketed"},{"name":"methylphenidate hydrochloride extended-release tablets","genericName":"methylphenidate hydrochloride extended-release tablets","slug":"methylphenidate-hydrochloride-extended-release-tablets","indication":"Attention deficit hyperactivity disorder (ADHD)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Pancrelipase microtablets","genericName":"Pancrelipase microtablets","slug":"pancrelipase-microtablets","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Methylphenidate extended-release; Atomoxetine","genericName":"Methylphenidate extended-release; Atomoxetine","slug":"methylphenidate-extended-release-atomoxetine","phase":"marketed","mechanism":"Methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity, while atomoxetine is a selective norepinephrine reuptake inhibitor.","indications":["Attention-deficit/hyperactivity disorder (ADHD) in children and adults"],"catalyst":""},{"name":"Pancrelipase microtablets","genericName":"Pancrelipase microtablets","slug":"pancrelipase-microtablets","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"methylphenidate hydrochloride extended-release tablets","genericName":"methylphenidate hydrochloride extended-release tablets","slug":"methylphenidate-hydrochloride-extended-release-tablets","phase":"phase_3","mechanism":"Methylphenidate hydrochloride is a central nervous system stimulant that works by increasing the levels of dopamine and norepinephrine in the brain.","indications":["Attention deficit hyperactivity disorder (ADHD)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"marketed":1,"phase_2":1,"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}